金水宝胶囊治疗肾脏疾病的快速卫生技术评估OACSTPCD

OBJECTIVE:To evaluate the efficacy,safety and economy of Jinshuibao capsules in the treatment of renal disease by rapid health technology assessment(HTA),so as to provide efficient and convenient evidence-based evidence for the clinic.METHODS:PubMed,the Cochrane Library,Wanfang Data,CNKI,VIP,CBM and other English and Chinese databases,official websites and related databases of institutions such as INAHTA,NICE,and CADTH were searched to obtain the systematic review/Meta-analysis,HTA report and pharmacoeconomic study of Jinshuibao capsules in the treatment of renal disease,the search period was from database establishment to Jun.2023.Literature was screened,information was extracted,quality was evaluated,and results were analyzed qualitatively based on inclusion and exclusion criteria.RESULTS:A total of 13 systematic review/Meta-analysis were enrolled(including 11 studies for diabetic nephropathy and 2 studies for chronic renal failure).Pharmacoeconomic studies and HTA reports were not retrieved.Results showed that Jinshuibao capsules combined with conventional therapy/angiotensin-converting enzyme inhibitors(ACEI)/angiotensin-Ⅱ receptor blockers(ARB)in the treatment of renal disease,the overall response rate was significantly better than that of the control group,and had advantages in reducing serum creatinine,blood erea nitrogen,24 h urine protein quantification,urinary albumin excretion rate,urinary trace albumin/urinary creatinine,triglyceride,cystatin C,urinary N-acetyl-β-D glucosaminidase,and increasing creatinine clearance rate;meanwhile,the incidence of adverse drug reactions was low and mild,with no severe adverse events and higher safety.CONCLUSIONS:The efficacy and safety of Jinshuibao capsules in the treatment of renal diseases are significant,and further pharmacoeconomic research is needed in the future.